# Paper Title:

Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study

# Introduction statement:

This study evaluated the safety and effectiveness of thalidomide for the treatment of COVID-19 patients with life-threatening symptoms.

# True statement:

The median duration of COVID-19 was shorter in the thalidomide group compared to the control group (respectively, 11.0 vs 23.0 days).

# Changes requested:

* Polarity shift
* Change numbers
* Masking
* Add content